Anticoagulation for non-valvular atrial aibrillation – towards a new beginning with ximelagatran

OBJECTIVES: Ximelagatran is a novel oral direct thrombin inhibitor. It has favorable pharmacodynamic properties, with a broad therapeutic range without the need for anticoagulation monitoring. We aimed to discover whether ximelagatran offers a genuine future replacement to warfarin for patients in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Boos, Christopher J, More, Ranjit S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420263/
https://www.ncbi.nlm.nih.gov/pubmed/15104801
http://dx.doi.org/10.1186/1468-6708-5-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420263/
https://www.ncbi.nlm.nih.gov/pubmed/15104801
http://dx.doi.org/10.1186/1468-6708-5-3

Ejemplares similares